Related Experiment Video
Updated: Dec 21, 2025

08:52
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
11.1K
Methods for Feature Selection in Down-Selection of Vaccine Regimens Based on Multivariate Immune Response Endpoints
Ying Huang1, Aliasghar Tarkhan2
1Fred Hutchinson Cancer Research Center, Seattle, WA 98109 USA.
Statistics in Biosciences
|May 19, 2020
Summary
Selecting relevant immune response endpoints improves vaccine regimen comparison. Our novel algorithms effectively reduce dimensions, enhancing clinical trial decision-making for HIV vaccine development.
Area of Science:
- Clinical Trials
- Biostatistics
- Immunology
Background:
- Comparing multiple candidate regimens using multiple endpoints is crucial in clinical trials, particularly for HIV vaccine development.
- Existing methods for ranking and selecting vaccine regimens can be challenged by correlated immune response endpoints.
Purpose of the Study:
- To propose novel algorithms for selecting parsimonious sets of immune response endpoints for regimen comparison.
- To enhance the performance of regimen down-selection processes through effective endpoint pre-selection.
Main Methods:
- Developed algorithms for immune response endpoint selection based on importance weights and correlation structures.
- Utilized extensive simulation studies to evaluate the proposed methods.
- Applied the method to a real-world HIV vaccine research case.
Main Results:
- Pre-selection of endpoints significantly improves the performance of subsequent regimen down-selection.
- The proposed algorithms effectively address the challenge of correlated endpoints in multi-endpoint comparisons.
- Demonstrated the practical utility of the method in HIV vaccine research.
Conclusions:
- Novel algorithms for endpoint selection enhance the efficiency and effectiveness of comparing clinical trial regimens.
- The methods offer a valuable approach for dimension reduction in multi-endpoint clinical research.
- Applicable to general clinical research beyond HIV vaccine development for optimizing regimen selection.

